Molecular methods for assessing tumor genome instability in acute myeloid leukemia

Laboratory diagnostics of acute myeloid leukemia enables accurate risk stratification of patients into prognostic groups according to modern classifications and facilitates personalized treatment selection. However, relapses and refractory forms still occur within each prognostic group. Some cytogenetic and molecular aberrations cannot be detected using standard diagnostic methods. Modern advanced laboratory techniques may uncover the mechanisms of tumor refractoriness and identify novel targets for therapy, which could improve acute myeloid leukemia diagnostics and patient prognosis.